Ignite Creation Date:
2024-05-06 @ 1:23 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04009499
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-24
First Post:
2019-07-02
Brief Title:
A Study to Assess the Long-term Safety Tolerability and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Open-Label Extension Study to Assess the Long-Term Safety Tolerability and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BE VITAL
Brief Summary:
This is a study to assess the long-term safety long-term efficacy and tolerability of bimekizumab administered subcutaneously sc in adult subjects with psoriatic arthritis PsA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-004725-86 | EUDRACT_NUMBER | None | None |